Role of favipiravir in the treatment of adult patients with moderate to severe COVID-1 19: a single-center, prospective, observational, sequential cohort study from Hungary 2 Balint Gergely SZABO^{1,2,*}, Katalin Szidonia LENART^{1,*}, Borisz PETRIK³, Zsofia 3 GASPAR³, Zsofia BALOGH¹, Zsuzsanna BANYAI¹, Emese BANYASZ¹, Jozsef BUDAI¹, 4 Eszter CZEL¹, Katalin FRIED¹, Adrienn HANUSKA¹, Noemi KISS-DALA¹, Csaba 5 LORINCZI¹, Krisztina NEMESI¹, Janos KADAR¹, Eva Livia NAGY¹, Akos OSVALD¹, 6 Edina PETROVICZ¹, Alexandra RICZU¹, Judit SZANKA¹, Beata SZATHMARY¹, Andrea 7 SZOMBATI¹, Szilvia TOTH¹, Zsuzsanna VARNAI¹, Orsolya WOLLER¹, Janos SZLAVIK¹, 8 Botond LAKATOS¹ 9 ¹ South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Saint 10 Ladislaus Campus (H-1097 Albert Florian ut 5-7., Budapest, Hungary) 11 ² Semmelweis University, School of PhD Studies (H-1085 Ulloi ut 26., Budapest, Hungary) 12 ³ Semmelweis University, Faculty of Medicine (H-1085 Ulloi ut 26., Budapest, 13 14 Hungary) * The authors contributed equally to the manuscript (in equo loco). 15 ORIGINAL RESEARCH ARTICLE 16 Corresponding author: Balint Gergely SZABO; szabo.balint.gergely@gmail.com; +36-17 30/644-5976. 18 Postal address: H-1097 Albert Florian ut 5-7., Budapest, Hungary. 19 20 **Keywords:** COVID-19, favipiravir, antiviral, cohort study **Running title:** Favipiravir treatment of adult COVID-19 patients 21 **Abstract word count**: 250 22 **Abstract character count**: 1807 23 Article word count: 2500 24 **Article character count**: 19700 25 **Number of tables: 3** 26 Number of references: 19 27

ABBREVIATIONS

- 29 ARDS – acute respiratory distress syndrome
- 30 BAL – bronchoalveolar lavage
- 31 COVID-19 – coronavirus disease-19
- 32 CRP – C-reactive protein
- 33 CS – cytokine storm
- CT computed tomography 34
- ECDC European Centre for Disease Prevention and Control 35
- EUCAST European Committee on Antimicrobial Susceptibility Testing 36
- FVP favipiravir 37
- ICU intensive care unit 38
- 39 IQR – interquartile region
- 40 LDH – lactate dehydrogenase
- LOS length of stay 41
- PCR polymerase chain reaction 42
- RCT randomized clinical trials 43
- SARS-CoV-2 severe acute respiratory syndrome coronavirus-2 44
- 45 SOC – standard of care
- STROBE Strengthening the Reporting of Observational studies in Epidemiology 46

ABSTRACT

- 48 **Background**: Preliminary data suggests that favipiravir might have a role in COVID-19
- treatment. Our aim was to assess the role of favipiravir in the treatment of COVID-19.
- Methods: A single-center, prospective, observational, sequential cohort study was performed
- among consecutive adults hospitalized with PCR-confirmed COVID-19 between March-
- 52 July, 2020. Patients were screened for inclusion by a priori criteria, and were included in the
- 53 favipiravir cohort if SOC+FVP, or the non-favipiravir group if SOC±other antiviral
- 54 medications without FVP were administered for >48 hours. Treatment allocation was done
- per national guidelines. For COVID-19 diagnosis and severity, ECDC and WHO definitions
- were utilized, and daily *per protocol* hospital follow-up was done. Primary composite end-
- 57 point was disease progression (14-day all-cause death, need for mechanical ventilation, or
- 58 immunomodulatory therapy). For statistical comparison, Fisher's exact test and Mann-
- 59 Whitney U-test were used.
- Results: In all, 75 patients were included per cohort. In the FVP cohort, chronic heart disease
- 61 (36/75, 48.0% vs. 16/75, 21.3%, p<0.01) and diabetes mellitus (23/75, 30.7% vs. 10/75,
- 62 13.3%, p<0.01) were more prevalent, hospital LOS (18.5±15.5 days vs. 13.0±8.5 days,
- 63 p<0.01) was higher. Disease progression (17/75, 22.7% vs. 10/75, 13.3%, p=0.13), 14-day all-
- cause death (9/75, 12.0% vs. 10/75, 13.3%, p=0.8) and need for mechanical ventillation (8/75,
- 65 10.7% vs. 4/75, 5.3%, p=0.22) were similar between groups. Immunomodulatory therapies
- were administered frequently among patients receiving FVP (10/75, 13.3% vs. 1/75, 1.3%,
- 67 p<0.01).
- 68 **Conclusions:** In this study, favipiravir did not seem to affect disease progression. Further data
- are needed to position this drug among the anti-SARS-CoV-2 armamentarium.

1. INTRODUCTION

As the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing, investigators are searching for therapeutic strategies to cure coronavirus disease-19 (COVID-19). As of September 2020, the number antiviral drugs proven to effectively inhibit viral replication is low [1]. Furthermore, it is not known which antivirals are unequivocally able to attenuate the pathological progression of COVID-19 in most patients with different severity. Favipiravir (FVP) is an antiviral pyrazinecarboxamide derivative, licensed for influenza in Japan. Data from the literature suggested that favipiravir might also be useful in COVID-19 treatment [2, 3]. Therefore, our goal was to assess the effect of favipiravir in the treatment of adult patients hospitalized at our centre with moderate to severe COVID-19.

2. METHODS

2.1 Study design and settings

A single-center, prospective, observational, sequential cohort study was performed among adults diagnosed and hospitalized with COVID-19 at our centre between March 15 – July 15, 2020 (first COVID-19 case was confirmed on March 4 in Hungary). Our centre is a national-level referreal institution, and the main COVID-19 centers of the country with >150 dedicated beds. The study was in accordance with the Helsinki Declaration, as well as national ethical standards. The institutional review board approved the study protocol, and informed consent was obtained from every patient.

2.2 Patient eligibility and inclusion

Consecutive adult (≥18 years of age) patients hospitalized at our centre during the study period with respiratory SARS-CoV-2 polymerase chain reaction (PCR) confirmed COVID-19 cases, irrespective of COVID-19 disease severity, were eligible for inclusion. To overcome selectional bias, all patients were prospectively screened for inclusion by our COVID-19 team (composed of attending physicians), by daily real-time visits at the ward and intensive care unit (ICU), and case assessment using hospital electronic records. Selection was done by using *a priori* inclusion/exclusion criteria. Inclusion criteria were: 1) PCR based confirmation of COVID-19 diagnosis in a clinically compatible case, with any disease severity; 2) received standard of care (SOC) or any of the exposure treatments for >48 hours after diagnosis. Exclusion criteria were: 1) the patient was intubated, died or discharged within ≤48 hours after diagnosis; 2) received SOC or any of the exposure treatments for ≤48

hours after diagnosis; 3) received any antiviral medication before diagnosis 4) patient data was not accessible through hospital electronic database.

Included patients were grouped into two sequential cohorts in 1:1 fashion, according to treatment exposures: favipiravir (FVP) cohort consisted of patients receiving SOC+FVP, non-favipiravir (non-FVP) cohort included patients who were administered SOC±other antiviral medications. Other possible antiviral medications were chloroquine, hydroxychloroquine, lopinavir/ritonavir, remdesivir and oseltamivir (please refer to the adequate section for details).

2.3 Data collection

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

A dedicated database was established for the study aim by manual extraction of data from hospital electronic records and written charts. Data was transferred anonymously to an a priori standardized case report form. Data collected: 1) age and gender; 2) comorbidities; 3) intensive care unit (ICU) admission during hospitalization; 4) length of stay (LOS) and ICU LOS; 4) clinical parameters at COVID-19 diagnosis (symptom onset, COVID-19 severity, supplementary oxygen demand, peripheral oxygen saturation, acute respiratory distress syndrome [ARDS], cytokine storm [CS], acute respiratory failure); 5) laboratory parameters at diagnosis (blood leucocyte, absolute neutrophil granulocyte, lymphocyte and platelet counts, hemoglobin, CRP, procalcitonin, serum ferritin, high sensitivity cardiac Troponin-I, serum interleukin-6, serum creatinine, LDH and D-dimer); 6) microbiological and radiological parameters at diagnosis (blood cultures and chest computed tomography [CT]); 7) characteristics of antimicrobial therapies and supportive care; 8) characteristics of immunomodulatory therapies; 9) study outcomes. Variables with ≥5% of missing measurements were omitted from final analysis, no imputation was seeked.

2.4 Diagnostic and therapeutic strategies at our centre during the pandemic

At our centre, we follow the European Centre for Disease Prevention and Control (ECDC) COVID-19 case definition for diagnosis ascertainment [4]. A clinically suspicious case presentation (cardinal symptoms: fever, dyspnea, cough) is confirmed if a respiratory specimen is positive for SARS-CoV-2 nucleic acid by PCR. Respiratory specimens are taken by a team of trained nurses with oro-/nasopharyngeal sampling in spontaneously breathing patients, or by mini-BAL in ventilated patients. Disease severity is determined by World Health Organization (WHO) criteria [5]. Disease onset is the first day of symptom apperance as reported by the patient, or day of first PCR positivity if symptom appearance could not be reported. The day of first SARS-CoV-2 PCR positivity is given as COVID-19 diagnosis day. Acute respiratory failure and ARDS were defined following the 2012 Berlin criteria, CS is diagnosed by trends of clinical and laboratory parameters and HScore, as proposed by *Mehta et al.* [6, 7].

At our centre, COVID-19 patient care is facilitated by standardized in-house diagnostic and therapeutic strategies, composed of written protocols and check-lists updated since March 2020 according to literature evidence. Physical examination, laboratory studies, arterial blood gas analyses are done daily. Imaging studies (chest X-ray and/or chest CT) are done on the day of COVID-19 diagnosis, and days +7, +14, and if disease progression (persistent fevers for \geq 72 hours, deteriorating hypoxaemia) or clinical instability (newly onset dyspnea, chest pain, hypotension, altered mentation) is documented. Every febrile (tympanal temperature \geq 37.8°C) patient has 2 sets of blood cultures taken. Testing for SARS-CoV-2 PCR negativity is initiated 24 hours after defervescence and clinical stability. Respiratory samples for SARS-CoV-2 PCR are collected every 48 hours, PCR negativity is documented on the day when two consecutive samples are proven to be negative. Daily follow-up of patients is done until death or hospital discharge, post-discharge follow-up is not routinely arranged. Microbiological diagnostics are performed at the Microbiology Laboratory of our centre.

COVID-19 antiviral therapies are allocated *per protocol*, in an open-label and non-randomized fashion (excluding patients in randomized clinical trials), but allocation is affected by drug availability on a national level. At our centre, treatment allocation is done in accordance with the "Hungarian Coronavirus Handbook" [8]. Before favipiravir introduction to Hungary (May 15, 2020), all patients received other antiviral medications: chloroquine (1g loading dose, 1x500mg maintenance thereafter, minimum of 7 days) or hydroxychloroquine (2x400mg loading dose, 2x200mg maintenance thereafter, min. of 5 days) or lopinavir/ritonavir (200/50mg in 2x2 capsules, min. of 7 days), depending on patient contraindications and drug availability. As the influenza season was overlapping with the first month of the epidemic in Hungary, oseltamivir (2x75mg) was also administered to patients, pending influenza A/B respiratory PCR results. Remdesivir was not available in Hungary during the study period. After favipiravir distribution, all patients received it *per protocol* in monotherapy at our centre (2x1600mg loading dose, 2x600mg maintenance thereafter, min. of 10 days). Patients are routinely receiving SOC (on-demand oxygen therapy, respiratory support, intravenous fluid replenishment, antipyretics, antitussive and bronchodilator drugs).

Empirical antibiotics per *Infectious Diseases Society of America* (IDSA) community-acquired pneumonia guideline are administered if disease progression or clinical instability is documented, immunomodulatory agents are administered in a clinical study to patients with CS or critical COVID-19, per COVID-19 team initiation [9].

2.5 Outcomes

The primary endpoint was disease progression, a negative composite of any of the following: 1) 14-day all-cause death, 2) need for mechanical ventilation, 3) need for immunomodulatory therapy for COVID-19 at ward or ICU. 14-day all-cause death was defined as exitus within 14 days from COVID-19 diagnosis during hospital stay. Need for mechanical ventilation was defined as a completed endotracheal intubation in relation to COVID-19, per decision of an ICU crash team. Need for immunomodulatory therapy was defined if any immunomodulatory drug was initiated at any dose, suggested by the "Hungarian Coronavirus Handbook" (at our centre, depending on availability: tocilizumab, ruxolitinib, baricitinib, intravenous immunoglobulin, reconvalescent plasma or systemic corticosteroids), excluding systemic corticosteroids started for alternative causes.

Secondary endpoints were 14-day all-cause mortality, need for mechanical ventilation, need for immunomodulatory therapy, rate of PCR negativity (at the end of hospitalization or sooner). Time analyses were done between cohorts by comparing time intervals from diagnosis day to disease progression, to all-cause mortality, to mechanical ventilation, to immunomodulatory therapy, to PCR negativity.

2.6 Statistical analysis

Continuous variables are expressed as median±interquartile range (IQR). Normality was checked with the *Shapiro–Wilks*-test. Categorical variables are expressed as absolute numbers (n) with relative percentages (%). Statistical comparisons were done with *Mann–Whitney* U-test *or Fisher*'s exact test. For identification of independent risk factors associating with disease progression, uni- and multivariate binomial logistic regression was performed. All plausible parameters and those with a *p*-value of \leq 0.1 in univariate analysis were entered into a forward stepwise multivariate logistic regression (entry criterion: p=0.05, removal criterion: p=0.1). Maximal number of predictors was estimated with the common 1:10 rule-of-thumb, goodness-of-fit was tested by the *Hosmer–Lemeshow* test. For all tests, a two-tailed p-value of \leq 0.05 determined statistical significance. Data collection was completed with Microsoft Office Excel 2016, tests were calculated using IBM SPSS Statistics 23. For

reporting, we adhere to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) Statement [10].

3. RESULTS

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

3.1 Baseline and clinical characteristics

In all, 150 patients were enrolled during the study period, 75 in both cohorts. Baseline and clinical characteristics are described in Table 1. Median age was 66.0±12.4 years, with representation of older patients in the FVP group (71.5±15.1 vs. 61.0±21.5 years, p<0.01). Genders and most comorbidities were equally distributed between cohorts, essential hypertension (57/75, 76.0% vs. 38/75, 50.7%, p<0.01) chronic heart disease (36/75, 48.0% vs. 16/75, 21.3%, p<0.01), diabetes mellitus (18/75, 24.0% vs. 6/75, 8.0%, p=0.01) and chronic cerebral disease (23/75, 30.7% vs. 10/75, 13.3%, p<0.01) were more prevalent in the FVP cohort. At diagnosis, 35/75 (53.3%) and 41/75 (54.7%) patients had severe disease in the FVP and non-FVP cohorts, respectively (p=0.41), and ARDS or CS was not documented. Need for oxygen supportation was needed in similar rates (27/75, 36.0% vs. 21/75, 28.5%, p=0.29). Documented bloodstream-infections were rare (1/75, 0.7%). Patients in the FVP group had higher white blood cell $(6.5\pm4.2\times10^9/L \text{ vs. } 5.5\pm3.3\times10^9/L, \text{ p=0.04})$, platelet counts $(225\pm117\times10^9/L \text{ vs. } 191\pm108\times10^9/L, \text{ p=0.03})$, serum creatinine $(86.0\pm49.3 \text{ } \mu\text{mol/L} \text{ vs.})$ $71.0\pm37.5 \, \mu mol/L$, p=0.03) and D-dimer (1163±2038 ng/mL vs. 850±479 ng/mL, p=0.03), lower hemoglobin levels (117±24 g/l vs. 131±20 g/L, p<0.01). The rate of chest CT positivity did not differ between cohorts (54 / 64, 84.4% vs. 13 / 14, 92.8%, p=0.67).

3.2 Outcomes, therapeutic approaches

Outcomes and therapeutic approaches are detailed in Table 2. Disease progression showed no statistically significant difference (17/75, 22.7% vs. 10/75, 13.3%, p=0.13) between cohorts. Rates of 14-day all-cause mortality (9/75, 12.0% vs. 10/75, 13.3%, p=0.8) and need for mechanical ventilation (8/75, 10.7% vs. 4/75, 5.3%, p=0.22) were also similar, need for immunomodulatory therapies was higher among patients receiving FVP (10/75, 13.3% vs. 1/75, 1.3%, p<0.01). FVP expuosure was not retained as an independent covariate in multivarite logistic regression modelling disease progression (Table 3.). Although there was a statistically non-significant tendency for higher PCR negativity rate (55/75, 73.0% vs. 43/75, 57.3%, p=0.05), median time to PCR negativity was significantly longer (22.0±15.5 days vs. 13.0±12.0 days, p<0.01) in the FVP cohort. Median time from diagnosis to disease

progression (8.0 \pm 9.0 days vs. 4.5 \pm 9.8, p=0.08) and time to exitus (16.0 \pm 14.0 days vs. 8.5±10.3 days, p=0.03) were both longer among patients receiving FVP.

Although supportive therapies were needed in equivalent rates (43/75, 57.3% vs. 46/75, 61.3%, p=0.73), hospital LOS (18.5±16.0 vs. 13.0±9.0 days, <0.01) was higher with similar ICU admissions (12/75, 16.0% vs. 5/75, 6.7%, p=007). In the non-FVP cohort, patients mostly received chloroquin or hydroxychloroquin (5/75, 6.7% vs. 61/75, 81.3%, p<0.01). Preferred antibiotics were azithromycin (19/75, 25.3% vs. 44/75, 58.7%, p<0.01) and ceftriaxon (13/75, 17.3% vs. 28/75, 37.3%, p<0.01). Tocilizumab was given frequently to patients with cytokine storm (9/75, 12.0% vs. 1/75, 1.3%, p=0.01).

4. DISCUSSION

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

4.1 Present study

We performed a single-center, prospective observational, sequential cohort study by enrolling 150 hospitalized adult patients with moderate to severe COVID-19, receiving either favipiravir or other antiviral medications with standard of care during the first 4 months of SARS-CoV-2 pandemic in Hungary. There was no statistically significant differences in time to antiviral therapy initiation from PCR positivity, COVID-19 disease severity, need for oxygen supportation and ICU admittance rates between cohorts. Disease progression, 14-day all-cause mortality, need for invasive mechanical ventilation and PCR negativity rate seemed to be unaffected by favipiravir exposure compared to other antivirals, and there was higher demand for immunomodulatory therapy administration among patients in the favipiravir cohort.

4.2 Previous studies

Pharmacological approaches, as well as clinical studies describing favipiravir treatment strategies for COVID-19 patients were reported in the literature. Although favipiravir demonstrated good in vitro inhibitory activity against SARS-CoV-2, the optimal pharmacological dose for COVID-19 treatment has yet to be determined, as the dose recommendations (as used in our study) based on pharmacokinetic experiments and clinical trials. Data of studies involving patients with other severe viral infections (influenzavirus, Ebolavirus) might be insufficient to maintain an adequate serum concentration, especially in critically ill patients [2, 11, 12]. Although a review found that favipiravir has a favourable safety profile concerning serious adverse events, the main side effects are hyperuricaemia,

teratogenicity and QTc prolongation. Establishment of long-term safety profile among

COVID-19 patients needs more pharmacovigilance data [13].

According to data from the literature, clinical usefulness of favipiravir in COVID-19 may somewhat be limited. A prospective clinical trial randomizing 240 adult patients in an 1:1 fashion with clinically confirmed COVID-19 to conventional therapy and umifenovir or favipiravir reported that although favipiravir administration associated with shorter time to defervescence and diminishment of cough, the drug could not significantly improve 7-day clinical recovery rate as a primary endpoint. Furthermore, rates of noninvasive mechanical ventilation, supplementary oxygen demand or all-cause mortality did not show differences between groups [14]. An open-labeled non-randomized study conducted by matching 35 microbiologically confirmed COVID-19 patients treated with favipiravir and 45 patients receiving lopinavir/ritonavir (all with additional interferon-alpha inhalation), within one week after onset of symptomps. Authors documented statistically higher improvement rates in chest imaging and faster viral clearance among patients receiving favipiravir, but effect of favipiravir on disease progression or mortality rates were not reported [15]. A recently published multicenter phase II/III randomized trial enrolled patients with moderate COVID-19 within a median of 6.7 days from start of symptomps. The primary efficacy endpoint was the elimination of SARS-CoV-2 by Day 10. On day 5, viral clearance was significantly more prevalant in the favipiravir arm (p=0.018), but on day 10 the difference was statistically nonsignificant (p=0.155). Authors conclude that in their pilot study, favipiravir appeared beneficious among moderately ill patients [16]. In small case series studies, favipiravir was administered with nafamostat mesylate or methylprednisolone for COVID-19 patients in different disease stages, but due to the lack of control groups and antiviral combination usage, the extent favipiravir effect on clinical cure remains ambiguous [17-19]. In all, we think that our findings could be reflected by data from current literature, and the role for favipiravir should not be overestimated in the treatment of adults with moderate to severe COVID-19.

4.3 Limitations

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

Our study had several limitations. As the pandemic is still ongoing, knowledge about COVID-19 is changing fast, and despite best efforts, *per protocol* treatment allocation might have been lagging behind literature evidence. National drug availability might have biased treatment allocation. The initiation of alternative antiviral medications might have been biased by (contra)indication. Age and comorbidity differences between our cohorts could represent the temporal progression of the epidemic in Hungary: younger people were affected sooner in

larger numbers, and this might have confounded some baseline characteristics due to the sequential cohort design. The number of included patients is relatively low, however, an exact *a priori* study size calculation was not feasible due to study design and enrollment. Chest CT was not readily obtainable from some patients due to technical reasons.

5. CONCLUSION

Among adult patients hospitalized with COVID-19, an overall beneficial effect of favipiravir on disease progression could not be proven in this study. Due to limitations, further prospective trial data are needed to elucidate the role of favipiravir in COVID-19 treatment.

TABLES 303

PARAMETER	Total (n=150)	FVP cohort (n=75)	Non-FVP cohort (n=75)	p value
Age (years, median±IQR, min-max)	66.0±12.4 (20.0–93.0)	71.5±15.1 (24.0–93.0)	61.0±21.5 (20.0–91.0)	< 0.01
Male gender (n, %)	76 (50.7)	37 (49.3)	39 (52.0)	0.74
ICU admission during hospitalization (n, %)	17 (11.3)	12 (16.0)	5 (6.7)	0.07
Time from disease onset to antiviral therapy				
(days, median±IQR, min-max)	3.0±6.0 (1-34)	2.0±3.0 (1-34)	7.5±9.0 (1–21)	< 0.01
Time from positive PCR to antiviral therapy ^a				
(days, median±IQR, min-max)	1.0±2.0 (1–31)	1.0±2.0 (1–31)	1.0±2.0 (1–6)	0.88
Comorbidities (n, %):				
- Essential hypertension	95 (63.3)	57 (76.0)	38 (50.7)	< 0.01
- Chronic heart disease	52 (34.7)	36 (48.0)	16 (21.3)	< 0.01
- Chronic vascular disease	14 (9.3)	10 (13.3)	4 (5.3)	0.1
- Chronic pulmonary disease	20 (13.3)	11 (14.7)	9 (12.0)	0.6
- Chronic renal disease	9 (6.0)	7 (9.3)	2 (2.7)	0.09
- Chronic hepatic disease	5 (3.3)	4 (5.3)	1 (1.3)	0.18
- Chronic cerebral disease	24 (16.0)	18 (24.0)	6 (8.0)	0.01
- Diabetes mellitus	33 (22.0)	23 (30.7)	10 (13.3)	< 0.01
- Active oncological malignancy	21 (14.0)	15 (20.0)	6 (8.0)	0.05
- Active hematolgical malignancy	13 (8.7)	9 (12.0)	4 (5.3)	0.16
- Systemic autoimmune disease	7 (4.7)	2 (2.7)	5 (6.7)	0.16
- Chronic systemic corticosteroid treatment	2 (1.3)	2 (2.7)	0	0.14
- Chronic systemic immunosuppressive treatment	2(1.3)	0	2 (2.7)	0.23
- Smoking	2(1.3)	2 (2.7)	0	0.16
Clinical characteristics at COVID-19 diagnosis:	2 (1.5)	2 (2.1)	0	0.10
- Peripheral oxygen saturation (%, median±IQR, min–max)	95±7 (51–99)	94±7 (51–99)	95±7 (78–99)	0.94
- Need for oxygen supportation (n, %)	48 (32.0)	27 (36.0)	21 (28.0)	0.29
- ARDS (n, %)	0	0	0	n.a.
- Acute respiratory failure (n, %)	1 (0.7)	0	1 (1.3)	n.a.
- CS (n, %)	0	0	0	n.a.
Severity of COVID-19 ^b (n, %):	0	0	U	II.a.
- Non-severe disease	74 (49.3)	40 (53.3)	34 (45.3)	
- Non-severe disease - Severe disease	74 (49.3) 76 (50.7)			0.41
	76 (30.7)	35 (46.7)	41 (54.7)	
Laboratory characteristics at COVID-19 diagnosis				
(median±IQR, min–max):	(2:27(2:217)	(5:40(07.017)	5.5.2.2.(2.2.16.4)	0.04
- White blood cell count (x10 ⁹ /L)	6.2±3.7 (2.3–21.7)	6.5±4.2 (2.7–21.7)	5.5±3.3 (2.3–16.4)	0.04
- Neutrophil granulocyte count (x10 ⁹ /L)	4.0±2.9 (0.4–20.1)	4.2±2.9 (0.4–20.1)	3.8±3.6 (1.6–14.9)	0.09
- Lymphocyte count (x10 ⁹¹ /)	1.2±0.7 (0.3–3.7)	1.2±0.8 (0.3–3.7)	1.1±0.7 (0.3–2.6)	0.07
- Platelet count (x10 ⁹ /L)	203±93 (12–743)	225±117 (12–743)	191±108 (78–414)	0.03
- Hemoglobin level (g/L)	124±32 (67–163)	117±24 (67–152)	131±20 (89–163)	< 0.01
- C-reactive protein (mg/L)	41±94 (1–316)	37±90 (1–229)	44.7±91.9 (1–316)	0.52
- Procalcitonin (μg/L)	0.0±0.1 (0–92.8)	0.1±0.1 (0–92.8)	0.0±0.1 (0–14.4)	0.08
- Interleukin-6 (pg/mL)	16.1±20.0 (2.7–76.9)	13.9±22.3 (2.7±76.9)	20.0±10.6 (15.6–46.0)	1.0
- Serum ferritin (µg/L)	397±520 (37–6001)	403±555 (37–6001)	364±219 (84–1268)	0.72
- Cardiac Troponin-I (ng/mL)	0.012±0.026 (0.001–2.171)	0.012±0.025 (0.001–2.171)	0.008±0.02 (0.002–0.056)	0.37
- Serum cratinine (µmol/L)	75.0±35.5 (36.0–470.0)	86.0±49.3 (36.0–446.0)	71.0±37.5 (37.0–470.0)	0.03
- Serum LDH (IU/L)	512±242 (214–2240)	491±232 (214–2240)	534±275 (241–1370)	0.51
- Serum D-dimer (ng/mL)	1111±1405 (160–49937)	1163±2038 (160–49937)	850±479 (316–1319)	0.03
Blood cultures taken per patient (n, %)	76 (50.7)	36 (48.0)	40 (53.3)	0.46
Detected bloodstream-infections (n, %)	1 (0.7)	1 (1.3)	0	0.31
Chest CT positive for COVID-19 / chest CT obtained	67 / 78 (85.9)	54 / 64 (84.4)	13 / 14 (92.8)	0.67

^a From first positive SARS-CoV-2 PCR, sampled from the respiratory tract

304

305

306

307

308 309 **Table 1.** Baseline and clinical characteristics of adult COVID-19 patients included in the study,

grouped by favipiravir administration.

^b Per World Health Organization criteria

n.a. Not applicable.

PARAMETER	Total (n=150)	FVP cohort (n=75)	Non-FVP cohort (n=75)	p value
Disease progression (n, %)	27 (18.0)	17 (22.7)	10 (13.3)	0.13
14-day all-cause mortality (n, %)	19 (12.7)	9 (12.0)	10 (13.3)	0.8
Need for invasive mechanical ventilation (n, %)	12 (8.0)	8 (10.7)	4 (5.3)	0.22
Need for immunomodulatory therapy (n, %)	13 (8.7)	10 (13.3)	1 (1.3)	< 0.01
Rate of PCR negativity (n, %)	99 (66.0)	55 (73.0)	43 (57.3)	0.05
Time from diagnosis to disease progression	7.0.7.0 (1.0.14.0)		4.510.9 (1.0.12.0)	0.08
(days, median±IQR, min-max)	7.0±7.0 (1.0–14.0)	8.0±9.0 (3.0-14.0)	4.5±9.8 (1.0–12.0)	0.08
Time from diagnosis to exitus	12.0±7.5 (1.0-50.0)	16.0±14.0 (6.0-50.0)	8.5±10.3 (2.0-14.0)	0.03
(days, median±IQR, min-max)	12.0±7.3 (1.0–30.0)	10.0±14.0 (0.0–30.0)	0.5±10.5 (2.0-14.0)	0.03
Time from diagnosis to mechanical ventilation	4.5±5.3 (1.0-12.0)	5.5±5.3 (3.0-12.0)	4.5±3.5 (1.0-12.0)	0.79
(days, median±IQR, min-max)	1.525.5 (1.0 12.0)	3.323.3 (3.0 12.0)	1.525.5 (1.0 12.0)	0.77
Time from diagnosis to immunomodulatory therapy	7.0±5.5 (3.0-14.0)	7.0±6.0 (3.0-14.0)	4.0±0 (4.0-4.0)	1.0
(days, median±IQR, min–max)	(*** ****)	()	()	
Time from positive PCR to PCR negativity	18.5±10.5 (3.0-55.0)	22.0±15.5 (3.0-55.0)	13.0±12.0 (3.0-32.0)	< 0.01
(days, median±IQR, min–max)				40.01
LOS (days, median±IQR, min–max)	15.0±10.8 (2.0–49.0)	18.5±15.5 (3.0–49.0)	13.0±8.5 (2.0–46.0)	<0.01
ICU LOS (days, median±IQR, min–max)	5.0±2.0 (1.0–25.0)	5.0±2.0 (2.0–12.0)	5.0±5.0 (1.0–25.0)	0.79
Supportive therapies needed ^a (n, %): - Nasal cannula	70 (52.7)	20 (50.7)	41 (547)	0.62
- Nasai cannula - Venturi mask	79 (52.7)	38 (50.7)	41 (54.7)	
	41 (27.3)	18 (24.0)	23 (30.7)	0.35
- Non-invasive ventilation	4 (2.7)	4 (5.3)	0	0.12
- Vasopressor therapy	11 (7.3) 1 (0.7)	8 (10.7)	3 (4.0)	0.11 0.31
- Renal replacement therapy - Parenteral nutrition	1 (0.7)	1 (1.3) 1 (1.3)	0	0.31
- Prone positioning	3 (2.0)	0	3 (4.0)	0.31
- Any	89 (59.3)	43 (57.3)	46 (61.3)	0.24
Antiviral therapies given (n, %):	07 (37.3)	+3 (31.3)	40 (01.5)	0.73
- Favipiravir	75 (50.0)	75 (100.0)	0	< 0.01
- Chloroquin/hydroxychloroquin	66 (44.0)	5 (6.7)	61 (81.3)	<0.01
- Oseltamivir	34 (22.7)	0	34 (45.3)	<0.01
- Lopinavir/ritonavir	7 (4.7)	0	7 (9.3)	0.01
- Remdesivir	0	0	0	n.a.
- Any ^b	139 (92.7)	75 (100.0)	64 (85.3)	<0.01
Antibacterial therapies given (n, %):		(,	()	
- Ampicillin	1 (0.7)	1 (1.3)	0	0.31
- Amoxicillin/clavulanate	5 (3.3)	1 (1.3)	4 (5.3)	0.17
- Cefazolin	3 (2.0)	3 (4.0)	0	0.24
- Ceftriaxon	41 (27.3)	13 (17.3)	28 (37.3)	< 0.01
- Cefepim	2 (1.3)	1 (1.3)	1 (1.3)	n.a.
- Piperacillin/tazobactam	20 (13.3)	13 (17.3)	7 (9.3)	0.14
- Meropenem	9 (6.0)	7 (9.3)	2 (2.7)	0.85
- Imipenem/cilastatin	15 (10.0)	12 (16.0)	3 (4.0)	0.01
- Vancomycin	3 (2.0)	3 (4.0)	0	0.08
- Linezolid	2 (1.3)	2 (2.7)	0	0.15
- Azithromycin	63 (42.0)	19 (25.3)	44 (58.7)	< 0.01
- Clarithromycin	1 (0.7)	1 (1.3)	0	0.31
- Levofloxacin	13 (8.7)	1 (1.3)	12 (16.0)	< 0.01
- Doxycyclin	10 (6.7)	0	10 (13.3)	< 0.01
- Gentamicin	4.0 (2.7)	4 (5.3)	0	0.04
- Any ^b	108 (72.0)	47 (62.7)	61 (81.3)	0.01
Immunomodulatory therapies given (n, %):	10 (5 =)	0 (17.0)	4 / 6 20	0.01
- Tocilizumab	10 (6.7)	9 (12.0)	1 (1.3)	0.01
- Ruxolitinib	0	0	0	n.a.
- Baricitinib	0	0	0	n.a.
- Intravenous immunoglobulin	2 (1.3)	2 (2.7)	0	0.49
- Reconvalescent plasma	0	0	0	n.a.
- Systemic corticosteroid	3 (2.0)	3 (4.0)	0	0.24
	4			

^a Excluding invasive mechanical ventilation.

311

312

313

314

315 316

310

Table 2. Outcomes and therapeutic approaches to adult COVID-19 patients included in the study, grouped by favipiravir administration.

^b Alone or in combination.

n.a. Not applicable.

317

318

319

	Disease progression No disease progress		Univariate analysis		Multivariate analysis	
	(n=27)	(n=123)	OR (95% CI)	p value	OR (95% CI)	p value
Age	74.0±23.1 (41.0–91.0)	66.0±12.9 (20.0–93.0)	1.04 (1.01-10.9)	0.01	-	
Male gender	12 (44.0)	64 (52.0)	0.74 (0.32-1.72)	0.47		
Time from disease onset to antiviral therapy	3.3±7.8 (1-34)	3.5±7.8 (1-34)	0.91 (0.81-1.01)	0.07*	n.a.	
Essential hypertension	19 (70.4)	76 (61.8)	1.64 (0.64-4.17)	0.3		
Chronic heart disease	18 (66.7)	34 (27.6)	5.81 (2.32– 14.70)	<0.01	4.27 (1.41–12.98)	0.01
Chronic cerebral disease	5 (18.5)	19 (15.4)	1.29 (0.43-3.84)	0.64		
Diabetes mellitus	10 (37.0)	23 (18.7)	2.69 (1.08-6.71)	0.03	-	
Need for oxygen supportation	16 (59.3)	32 (26.0)	4.13 (1.74-9.80)	0.01	-	
Severe COVID-19	26 (96.3)	50 (27.0)	38.5 (5.0– 333.30)	<0.01	21.28 (2.32–200.0)	<0.01
Any supportive therapy needed	26 (96.3)	63 (51.2)	5.10 (1.82– 14.30)	<0.01	_	
Any antibacterial therapy needed	22 (81.5)	86 (69.9)	1.89 (0.67–5.37)	0.23		
Any antiviral therapy needed	25 (92.6)	114 (92.7)	1.01 (0.21-4.98)	0.98		
Treatment with faviniravir	17 (63 0)	58 (47.2)	1 91 (0 81-4 48)	0.14	_	

^{*}The parameter was not included in the final model as co-linearity was not proven by the Box-Tidwell test with *Bonferroni*'s *post hoc* correction (p < 0.01)

Table 3. Independent predictors of disease progression among adult COVID-19 patients included in the study, grouped by progression occurence

TRANSPARENCY DECLARATION

- 323 **Conflict of interest**: The authors declare no conflicts of interest regarding this article. The
- 324 ICMJE Form for Disclosure of Potential Conflicts of Interest was completed by the
- 325 corresponding author on behalf of all co-authors.
- Funding: The article itself did not receive any external funding. BGSz received the EFOP-
- 3.6.3-VEKOP-16-2017-00009 Doctorate Grant, and was supported by the *ÚNKP-19-3-I-SE*-
- 328 74 New National Excellence Program of the Ministry of Innovation and Technology of
- Hungary. The funding sources had no involvement in the preparation, writing, interpretation,
- or submission of this article.

- 331 **Acknowledgements:** The authors would like to thank the healthcare workers of our centre for
- their sacrifice during these times. Together, we are stronger. Preliminary results of the study
- were presented at ECCVID 2020 (September 23–25, 2020).
- Access to data: Anonymised data of patients are available from the corresponding author on
- reasonable request.
- Authors' contributions: BGSZ and LKSZ contributed equally to the manuscript (in equo
- 337 loco). BGSZ: management of patients, data collection, data analysis, preparation of study
- protocol, preparation of the manuscript; LKSZ: management of patients, data collection, data
- analysis, preparation of study protocol, preparation of the manuscript; BP: data collection,
- data analysis; ZSG: data collection, data analysis; ZSB: management of patients, review of the
- manuscript; ZSB: management of patients, review of the manuscript; EB: management of
- patients, review of the manuscript; JB: management of patients, review of the manuscript; EC:
- management of patients, review of the manuscript; KF: management of patients, review of the
- manuscript; AH: management of patients, review of the manuscript; NKD: management of
- patients, review of the manuscript; CSL: management of patients, review of the manuscript;
- 346 KN: management of patients, review of the manuscript; JK: management of patients, review
- of the manuscript; ELN: management of patients, review of the manuscript; AO: management
- of patients, review of the manuscript; EP: management of patients, review of the manuscript;
- AR: management of patients, review of the manuscript; JSZ: management of patients, review
- of the manuscript; BSZ: management of patients, review of the manuscript; ASZ:
- management of patients, review of the manuscript; SZT: management of patients, review of
- the manuscript; ZSV: management of patients, review of the manuscript; OW: management of
- patients, review of the manuscript; JSZ: management of patients, review of the manuscript,

COVID-19 Team Leader; BL: management of patients, preparation of study protocol,

preparation and review of the manuscript.

Ethics approval: The Institutional Review Board of South Pest Central Hospital, National Institute of Hematology and Infectious Diseases (Budapest, Hungary) approved the study protocol. Approval for the use of off-label investigational drugs was granted by our institutional review board, as well as the National Institute of Pharmacy and Nutrition in relation to the COVID-19 surge in Hungary (ogyei.gov.hu/tajekoztato_a_veszelyhelyzet_megszunesevel_kapcsolatos_a_covid_19_jarvany_idejen_kulonos_meltanylast_erdemlo_betegellatasi_erdekhez_kotheto_gyogyszeralkalmazas ok_bejelenteserol).

REFERENCES

- [1] National **Institutes** of Health. COVID-19 Treatment Guidelines. 2020. 365
- https://www.covid19treatmentguidelines.nih.gov/whats-new/. (Accessed 2020.09.01). 366
- 367 [2] Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G, et al. Favipiravir strikes
- the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv 2020. 368
- 369 [3] Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob
- Chemother 2020;75:2013-4. 370
- [4] European Centre for Disease Prevention and Control. Case definition for coronavirus 371
- disease 2019 (COVID-19), as of 29 May 2020. 2020. https://www.ecdc.europa.eu/en/covid-372
- 19/surveillance/case-definition. (Accessed 2020.09.01). 373
- World Health Organization. Clinical COVID-19. 2020. 374 management of
- 375 https://www.who.int/publications/i/item/clinical-management-of-covid-19. (Accessed
- 2020.09.01.). 376
- [6] Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. 377
- Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-33. 378
- [7] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: 379
- consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4. 380
- [8] Emberi Erőforrások Minisztériuma. A 2020. évben azonosított új koronavírus (SARS-381
- CoV-2) okozta fertőzések (COVID-19) megelőzésének és terápiájának kézikönyve. 2020. 382
- https://koronavirus.gov.hu/sites/default/files/sites/default/files/imce/magyar koronavirus kezi 383
- konyv 2020.06.25.pdf. (Accessed 2020.09.01.) [In Hungarian]. 384
- 385 [9] Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and
- Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice 386
- Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am 387
- 388 J Respir Crit Care Med 2019;200:e45-e67.
- [10] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The 389
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: 390
- guidelines for reporting observational studies. Lancet 2007;370:1453-7. 391
- [11] Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, et al. Pharmacokinetics of 392
- Favipiravir in Critically III Patients With COVID-19. Clin Transl Sci 2020;13:880-5. 393
- 394 [12] Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for
- 2019-nCoV Infection. Clin Pharmacol Ther 2020;108:242-7. 395

- [13] Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir a potential 396
- treatment in the COVID-19 pandemic? J Virus Erad 2020;6:45-51. 397
- 398 [14] Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for
- COVID-19: A Randomized Clinical Trial. medRxiv 2020. 399
- [15] Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with 400
- Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) 2020. 401
- [16] Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, 402
- et al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a 403
- 404 Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis 2020.
- [17] Murohashi K, Hagiwara E, Kitayama T, Yamaya T, Higa K, Sato Y, et al. Outcome of 405
- early-stage combination treatment with favipiravir and methylprednisolone for severe 406
- COVID-19 pneumonia: A report of 11 cases. Respir Investig 2020. 407
- 408 [18] Doi K, Ikeda M, Hayase N, Moriya K, Morimura N, Group C-US. Nafamostat mesylate
- treatment in combination with favipiravir for patients critically ill with Covid-19: a case 409
- 410 series. Crit Care 2020;24:392.

- [19] Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of 411
- 412 favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care 2020;24:413.